ArteraAI Prostate Test (Post-RP) Added to NCCN Guidelines
The addition builds on Artera’s inclusion in the guidelines for localized prostate cancer, extending decision support to pati [...]
Artera Earns Frost & Sullivan’s 2026 Technology Innovation Leadership Recognition for AI-Powered Breast Cancer Risk Stratification
Recognition highlights Artera's clinical evidence and its role in advancing precision oncology SAN FRANCISCO – October 29, 20 [...]
New Data Highlight Artera’s MMAI Consistency Across Diverse Patient Populations at ASTRO 2026
Five abstracts spanning global patient cohorts and U.S. cooperative trials reinforce the prognostic and predictive power of A [...]
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
Validation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit Concordance analysis between MMAI and [...]
Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC)
First digital pathology-based test to provide individual risk estimates to help inform treatment planning in mHSPC SAN FRANCI [...]
Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding Its AI Platform to Breast Cancer
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announ [...]
Artera Secures CE Marking for Its AI Prostate and Breast Cancer Assays, Unlocking Global Expansion
Dual regulatory milestones establish Artera as a global AI leader in precision oncology SAN FRANCISCO, April 21, 2026— Artera [...]
Artera Debuts ArteraAI Prostate Test (Post‑RP), Expanding its Oncology Portfolio
-Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, today announced the commercial launch of [...]
Artera Unveils Data Demonstrating Prognostic and Predictive Utility in Breast Cancer at SABCS 2025
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announ [...]